Figures & data
Table 1. Overview of ongoing clinical trials of gemtuzumab ozogamicin in AML, also enrolling children.
Table 2. Search terms electronic databases.
Table 3. Overview of the most important variables of all eligible studies in pediatric AML, single-agent therapy.
Table 4. Overview of the most important variables of all eligible studies in pediatric AML, combination therapy.
Figure 2. Scatterplot for the single dose of gemtuzumab ozogamicin in relation to incidence of VOD. Single-agent therapy.
![Figure 2. Scatterplot for the single dose of gemtuzumab ozogamicin in relation to incidence of VOD. Single-agent therapy.](/cms/asset/050e224f-d39d-4677-a0b6-d5bda70a130d/iery_a_1129903_f0002_b.gif)
Figure 3. Scatterplot for the cumulative dose of gemtuzumab ozogamicin in relation to incidence of VOD. Single-agent therapy.
![Figure 3. Scatterplot for the cumulative dose of gemtuzumab ozogamicin in relation to incidence of VOD. Single-agent therapy.](/cms/asset/6700e074-8020-493b-bc0f-5b31a36e48bc/iery_a_1129903_f0003_b.gif)